Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
102last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
The Wall Street Journal102d agoneutral
FTC Sues Hims & Hers, Alleging Unlawful Sharing of Data, Deceptive BillingReuters102d agoneutral
Exclusive-US FTC suing Hims & Hers for sending user health info to Meta, SnapBenzinga106d agoneutral
FDA Panel Narrowly Backs Four Peptides - Hims & Hers Stock in the SpotlightInvestor's Business Daily108d agoneutral
Hims, The Surprise Winner Of The FDA Showdown With Peptides, Bounds HigherInvestor's Business Daily115d agoneutral
This Trade Offers Two Ways To Profit From Hims & Hers StockSimply Wall St.159d agoneutral
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth ProspectsProactive166d agoneutral
Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofAReuters171d agoneutral
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiryStockStory172d agoneutral
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings CallStockStory179d agoneutral
Hims & Hers Health (HIMS) Reports Q1: Everything You Need To Know Ahead Of EarningsSimply Wall St.180d agoneutral
Why Hims & Hers Health (HIMS) Is Up 6.9% After GLP-1 Pivot Spurs Q1 Loss And Guidance Hike